Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone

DB15235InvestigationalSmall molecule

Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors).

Mechanism: Pharmacologically active on Iron
Curator reviewed
Formula / weight: C₁₉H₂₃N₅S · 353.49 g/mol (avg)
Also known as: DP4CYCH4MT

Resolves to

Compound

UNII6068Z4Y7QICAS1382469-39-7ChEMBLCHEMBL2203744

Structure

InChIKeyGNLZNQJBZNOUBM-UHFFFAOYSA-NSMILESCN(C1CCCCC1)C(=S)NN=C(C1=CC=CC=N1)C1=NC=CC=C1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account